Traders should monitor the actual data release after the April 19 presentation for survival rate trends, which could influence investor perception of KIMMTRAK’s durability and market positioning. Positive data may support valuation, especially given the lack of competing therapies.
IMCR drugs
IMCR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 18 $30.04entry
- T+1 · 8mo ago 0.00%α +0.27% · $30.04
- T+5 · 8mo ago +0.80%α +1.51% · $30.28
- T+20 · 7mo ago +4.46%α −1.59% · $31.38
- T+60 · 5mo ago −4.73%α −16.25% · $28.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immunocore announced it will present five-year overall survival data from the KIMMTRAK Phase 3 trial in metastatic uveal melanoma at the 2026 AACR Annual Meeting. This represents the longest OS follow-up in a randomized trial for this patient population, potentially reinforcing KIMMTRAK's clinical benefit in a rare and aggressive cancer with limited treatment options.
Key Facts
- Immunocore will present five-year overall survival data from the KIMMTRAK Phase 3 trial at AACR 2026.
- Data comes from a randomized trial in HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma.
- Presentation includes additional insights: subsequent treatments, treatment beyond progression, and prognostic factors.
- KIMMTRAK is already approved in the U.S., EU, Canada, Australia, and the UK for this indication.
- No financial results, revenue figures, or guidance updates were included in the release.
Financial Impact
Potential long-term commercial reinforcement of KIMMTRAK, but no immediate financial impact disclosed
Risk Factors
- Five-year OS data could show diminishing survival benefit or increased late toxicity, negatively impacting sentiment.
- No new patient enrollment or trial expansion announced; commercial uptake remains limited by HLA-A*02:01 biomarker restriction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257672 |
Track record
14 reports on IMCR
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +28.39% at T+60 after the May 31, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $32.38 Now $28.88 −10.81% settles Feb 8
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $30.99 Now $28.88 −6.81% settles Feb 4
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Bearish 5/10 Entry $30.99 Now $28.88 +6.81% settles Feb 4
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $31.27 Now $28.88 −7.64% settles Jan 27
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $29.48 Now $28.88 −2.04% settles Jan 12
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $29.41 Now $28.88 −1.80% settles Jan 4
- Sep 14, 20269w ago 8-K Bullish 6/10 Entry $32.46 Now $28.88 −11.03% settles Dec 8
- Aug 6, 202614w ago 8-K Mixed 5/10 Entry $34.50 to $30.49 Now $28.88 −16.29% ▼ −11.62% −9.95% vs SPY
- May 31, 202624w ago Press Release Bullish 6/10 Entry $29.13 to $37.40 Now $28.88 −0.86% ▲ +28.39% +27.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers